Company intelligence / Profile preview

MiMARK

Barcelona, Catalonia/Catalunya, Spainmimark.es ↗

Ownership: Private
Development stage: Preclinical

Overview

MiMARK’s lead product, WomEC, is an in vitro diagnostic immunoassay that analyzes protein biomarkers in uterine fluid to detect endometrial cancer. The test demonstrates 99% sensitivity and 87% specificity as a non-invasive “rule-out” tool for endometrial cancer diagnosis. It aims to replace invasive hysteroscopies with a more accurate, efficient, and comfortable alternative. Additional diagnostics for ovarian cancer and endometriosis are under development[4][5].

Therapeutic areas: OncologyWomen's Health
Modalities: In vitro diagnostic testImmunoassayProtein biomarker analysis
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

WomEC

Pre-clinical

Indications: Endometrial cancer

Partnerships

EIT Health[5]Vall d'Hebron Research Institute/VHIR[7]PharmStars accelerator program[3][4]

Beyond the preview

Go deeper on MiMARK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiMARK.

Explore the full profile